SHANGHAI,Jan. 8, 2016/PRNewswire/ -- Zai Lab Ltd., an innovative biopharmaceutical company, announced today that it has secured over$100Min its Series B financing from a group of leading healthcare investors. The investment was led by Advantech Capital and included OrbiMed.The existing investors Qiming Ventures, Sequoia Capital China, and TF Capital all participated in the round.

The funding will be used to supportZai Lab'sresearch and development programs as well as the company's ongoing in-licensing and commercialization efforts.Zai Labhas built a world class organization with global expertise to focus on developing novel medicines in areas of large unmet medical needs.

Commenting on the financing, Dr.Samantha Du, founder, Chairman and CEO said: "We welcome both US andChina'sleading investors to join this significant round of financing and with all existing investors participating. This financing will allow Zai to further capitalize on the rapid growing opportunity inChinaand to bring transformative treatments to patients with highly unmet medical needs."

Mr.Jianming Yu, Founder & Managing Partner of Advantech Capital, said, "We are delighted to partner withZai Lab'steam of industry veterans in this exciting time of rapid growth inChina'shealthcare sector. Dr. Du and her team are building a world-class company. We are pleased with the progress they have made and see significant potential inZai Lab."

About Zai Lab

Zai Labis a leading biopharmaceutical company based inChinafocused on discovering, developing and commercializing innovative medicines for unmet medical needs globally. The company is building a strong portfolio of therapeutic programs aimed at transforming patients' lives.Zai Labhas a world class leadership team with deep experience at global pharmaceutical and biotech organizations. The team has a strong track record of success-- successfully taken five novel drug candidates into clinical trials inChina, pioneered new regulatory channels, secured regulatory approvals in record times, conducted multiple IND trials in the US, and brought the firstChinadiscovered drug into Global Phase III trials.Zai Labis committed to build a globally leading drug research and development powerhouse with a culture of excellence and teamwork and a strong focus on fostering innovation and creativity.